Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 4Ovarian Neoplasms 4Squamous Cell Carcinoma of Head and Neck 1SCLC,Extensive Stage 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 18Specimen Handling 17Magnetic Resonance Spectroscopy 12Biopsy 12Paclitaxel 9Carboplatin 8Radiosurgery 7Nivolumab 7trastuzumab deruxtecan 6Pemetrexed 6Leucovorin 6Irinotecan 6Fulvestrant 6Fluorouracil 6Bevacizumab 6palbociclib 5Oxaliplatin 5Letrozole 5Gemcitabine 5Cetuximab 5Taxes 4Cisplatin 4Capecitabine 4olaparib 3enzalutamide 3durvalumab 3Ipilimumab 3Docetaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × niraparib × 30 days × Clear all
NCT04992013 2026-06-01

Niraparib in Tumors Metastatic to the CNS

Massachusetts General Hospital

Phase 2 Active not recruiting
20 enrolled
CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡